Literature DB >> 16048970

Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains.

Helio S Sader1, Thomas R Fritsche, Koné Kaniga, Yigong Ge, Ronald N Jones.   

Abstract

PPI-0903M is a novel N-phosphono-type cephalosporin active against oxacillin-resistant staphylococci and many other gram-positive organisms. This study evaluated the in vitro activity and spectrum of PPI-0903M against 1,478 recent clinical isolates collected from 80 medical centers (22 countries). PPI-0903M demonstrated broader in vitro activity against gram-positive bacteria, particularly against multidrug-resistant staphylococci and streptococci of current clinical concern, than currently available extended-spectrum cephalosporins while maintaining similar activity against gram-negative pathogens.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16048970      PMCID： PMC1196228          DOI： 10.1128/AAC.49.8.3501-3512.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Increase in community-acquired methicillin-resistant Staphylococcus aureus in children.

Authors:  A L Frank; J F Marcinak; P D Mangat; P C Schreckenberger
Journal:  Clin Infect Dis       Date:  1999-10       Impact factor: 9.079

2.  In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci.

Authors:  Ronald N Jones; Lalitagauri M Deshpande; Alan H Mutnick; Douglas J Biedenbach
Journal:  J Antimicrob Chemother       Date:  2002-12       Impact factor: 5.790

3.  Bacterial resistance: origins, epidemiology, and impact.

Authors:  David M Livermore
Journal:  Clin Infect Dis       Date:  2003-01-15       Impact factor: 9.079

4.  In vitro activities of RWJ-54428 (MC-02,479) against multiresistant gram-positive bacteria.

Authors:  S Chamberland; J Blais; M Hoang; C Dinh; D Cotter; E Bond; C Gannon; C Park; F Malouin; M N Dudley
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

Review 5.  Streptococcus pneumoniae as an agent of nosocomial infection: treatment in the era of penicillin-resistant strains.

Authors:  F Paradisi; G Corti; R Cinelli
Journal:  Clin Microbiol Infect       Date:  2001       Impact factor: 8.067

6.  A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital.

Authors:  M Wootton; R A Howe; R Hillman; T R Walsh; P M Bennett; A P MacGowan
Journal:  J Antimicrob Chemother       Date:  2001-04       Impact factor: 5.790

7.  The impact of penicillin resistance on the outcome of invasive Streptococcus pneumoniae infection in children.

Authors:  K E Rowland; J D Turnidge
Journal:  Aust N Z J Med       Date:  2000-08

Review 8.  Penicillin-resistant pneumococci-implications for management of community-acquired pneumonia and meningitis.

Authors:  Hisham M Ziglam; Roger G Finch
Journal:  Int J Infect Dis       Date:  2002-03       Impact factor: 3.623

9.  Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae.

Authors:  John R Lonks; Javier Garau; Lucía Gomez; Mariona Xercavins; Anna Ochoa de Echagüen; Ilana F Gareen; Philip T Reiss; Antone A Medeiros
Journal:  Clin Infect Dis       Date:  2002-08-09       Impact factor: 9.079

10.  In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599.

Authors:  Yuji Iizawa; Junko Nagai; Tomoyasu Ishikawa; Shohei Hashiguchi; Masafumi Nakao; Akio Miyake; Kenji Okonogi
Journal:  J Infect Chemother       Date:  2004-06       Impact factor: 2.211
View more
  50 in total

1.  In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae.

Authors:  Dora E Wiskirchen; Jared L Crandon; Guilherme H Furtado; Gregory Williams; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2011-04-25       Impact factor: 5.191

Review 2.  Development of novel antibacterial drugs to combat multiple resistant organisms.

Authors:  Matteo Bassetti; Elda Righi
Journal:  Langenbecks Arch Surg       Date:  2015-02-11       Impact factor: 3.445

3.  In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime.

Authors:  Asunción Fenoll; Lorenzo Aguilar; Olga Robledo; María-José Giménez; Juan-José Granizo; Donald Biek; David Tarragó
Journal:  Antimicrob Agents Chemother       Date:  2008-08-25       Impact factor: 5.191

4.  In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.

Authors:  Steven D Brown; Maria M Traczewski
Journal:  Antimicrob Agents Chemother       Date:  2008-12-29       Impact factor: 5.191

5.  In vitro activity of ceftaroline against a broad spectrum of recent clinical anaerobic isolates.

Authors:  David R Snydman; Nilda V Jacobus; Laura A McDermott
Journal:  Antimicrob Agents Chemother       Date:  2010-11-01       Impact factor: 5.191

6.  Defining daptomycin resistance prevention exposures in vancomycin-resistant Enterococcus faecium and E. faecalis.

Authors:  B J Werth; M E Steed; C E Ireland; T T Tran; P Nonejuie; B E Murray; W E Rose; G Sakoulas; J Pogliano; C A Arias; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

7.  Inhibition of Streptococcus pneumoniae penicillin-binding protein 2x and Actinomadura R39 DD-peptidase activities by ceftaroline.

Authors:  Astrid Zervosen; André Zapun; Jean-Marie Frère
Journal:  Antimicrob Agents Chemother       Date:  2012-11-12       Impact factor: 5.191

8.  In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure.

Authors:  Amira A Bhalodi; Mao Hagihara; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2013-11-11       Impact factor: 5.191

Review 9.  Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus.

Authors:  George G Zhanel; Grace Sniezek; Frank Schweizer; Sheryl Zelenitsky; Philippe R S Lagacé-Wiens; Ethan Rubinstein; Alfred S Gin; Daryl J Hoban; James A Karlowsky
Journal:  Drugs       Date:  2009       Impact factor: 9.546

10.  Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.

Authors:  Yigong Ge; David Maynard; Douglas E Rickert
Journal:  Antimicrob Agents Chemother       Date:  2009-11-30       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.